



# Lotus Eye Hospital And Institute Limited



CIN No. : L85110TZ1997PLC007783

770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore - 641 014.

Tel : 0422 - 4229900, 4229999 Fax : 0422 - 4229933

## R.S. PURAM

155B, East Periasamy Road, Near Chinthamani,  
North Coimbatore, R.S. Puram,  
Coimbatore - 2. Phone : 0422 - 4239900, 4239999

## METTUPPALAYAM

No. 28, Coimbatore Main Rd,  
Opp. Bus Stand, MTP - 634 301.  
Phone : 04254 - 223223, 224224

## TIRUPUR

Tiruppur : Near Santha Pettai Bus Stop,  
Thennampalayam, Palladam Road,  
Tiruppur-604.  
Tel. : 0421 - 4346060, 4219999

## SALEM

86, Brindhavan Road, Fairlands  
Salem - 636 004.  
Ph. : 0427 - 4219900, 4219999

E-mail : [info@lotuseye.org](mailto:info@lotuseye.org)

Website : [www.lotuseye.org](http://www.lotuseye.org)

November 14, 2022

<b>BSE Limited</b> <b>Phiroze Jeejeebhoy Towers</b> <b>Dalal Street</b> <b>Mumbai- 400001</b> <b>Scrip Code: 532998</b>	<b>National Stock Exchange of India Limited</b> <b>5th Floor, Exchange Plaza</b> <b>Bandra (East)</b> <b>Mumbai – 400 051</b> <b>Scrip Code: LOTUSEYE</b>
---	---

Dear Sir/Madam

### **Sub: Outcome of Board Meeting held on November 14<sup>th</sup> 2022**

In terms of Regulation 30 read with Part A Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on November 14<sup>th</sup> 2022 has transacted the following business:

Approved unaudited standalone results for the quarter and period ended September 30, 2022.

The Board meeting commenced by 04:30 P.M and ended by 01:05 P.M

We request you to please take the same on your record.

**Yours Faithfully**

**For Lotus Eye Care Hospital and Institute Limited**

**M Achuth Menon**

**Company secretary & Compliance Officer**

**Membership No – A63980**

## Kochi

533/33A-33F, Tejas Tower  
SA Road, Kadavanthara,  
Kochi, Kerala - 682 020.  
Tel. : 0484 - 2322333, 2322444

*Always for you*

## Kochi

229A, Kurisingal House  
Mulanthuruty Post  
Kochi, Kerala - 682 314.  
Tel. : 0484 - 2743191, 2743121

# ANBARASU & JALAPATHI

CHARTERED ACCOUNTANTS



To  
The Board of Directors,  
Lotus Eye Hospital and Institute Limited,  
Coimbatore.

## Limited review report for the Quarter/Half year ended September 30, 2022

1. We have reviewed the accompanying statement of unaudited financial results of Lotus Eye Hospital and Institute Limited ("the Company") for the quarter/half year ended September 30, 2022, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This statement which is the responsibility of the Company's management and approved by the Board of Directors at their meeting on November 14, 2022, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting Standards and other recognized accounting practices and policies, have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Coimbatore,  
November 14, 2022.

For Anbarasu & Jalapathi  
Chartered Accountants  
Firm Registration No.: 010795S

CA. S. Anbarasu  
Partner

Membership No.: 212299

UDIN: 22212299BDCFYV5295



## Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014

Phone no: 0422-4229900, Fax: 0422-4229933, E-mail: companysecretary@lotuseye.org, Website: www.lotuseye.org

### Statement of Un-audited Financial Results for the Half year/Quarter ended September 30, 2022

(Rs. in lakhs)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30-Sep-22 (Un-audited)	30-Jun-22 (Un-audited)	30-Sep-21 (Un-audited)	30-Sep-22 (Un-audited)	30-Sep-21 (Un-audited)	31-Mar-22 (Audited)
	<b>Income:</b>						
I.	Revenue from operations	1,186.41	1,187.43	1,081.11	2,373.84	1,673.31	3890.99
II.	Other income	23.11	23.89	20.93	46.99	38.26	88.58
III.	<b>Total income (I+II)</b>	<b>1,209.52</b>	<b>1,211.32</b>	<b>1,102.04</b>	<b>2,420.83</b>	<b>1,711.57</b>	<b>3,979.57</b>
	<b>Expenses:</b>						
IV.	(a) Cost of materials consumed	211.67	209.21	183.83	420.88	271.69	651.08
	(b) Purchase of stock-in-trade	181.95	181.56	164.14	363.51	250.82	568.82
	(c) Changes in inventories	(9.67)	(17.44)	(8.11)	(27.11)	(2.35)	(7.35)
	(d) Service expenses	174.70	166.46	166.88	341.16	287.89	615.58
	(e) Employee benefit expense	219.88	207.31	189.92	427.18	329.88	730.58
	(f) Finance costs	2.60	3.04	3.62	5.64	5.86	12.81
	(g) Depreciation and amortization expense	75.13	68.07	59.51	143.20	112.25	250.10
	(h) Other expenses	232.64	207.74	175.66	440.38	310.00	747.60
	<b>Total expenses (IV)</b>	<b>1,088.90</b>	<b>1,025.95</b>	<b>935.46</b>	<b>2,114.84</b>	<b>1,566.04</b>	<b>3,569.22</b>
V.	<b>Profit/(loss) before exceptional items and tax (III-IV)</b>	<b>120.62</b>	<b>185.37</b>	<b>166.58</b>	<b>305.99</b>	<b>145.53</b>	<b>410.35</b>
VI.	Exceptional items	(0.14)	-	(0.20)	(0.14)	(0.20)	(1.00)
VII.	<b>Profit/(loss) before tax (V+VI)</b>	<b>120.48</b>	<b>185.37</b>	<b>166.38</b>	<b>305.85</b>	<b>145.33</b>	<b>409.35</b>
VIII.	<b>Tax expenses</b>						
	(a) Current tax	28.26	42.50	41.03	70.76	41.03	108.57
	(b) Deferred tax	2.19	5.75	(0.09)	7.93	(1.48)	2.34
	<b>Total tax expense (VIII)</b>	<b>30.45</b>	<b>48.25</b>	<b>40.94</b>	<b>78.69</b>	<b>39.55</b>	<b>110.91</b>
IX.	<b>Net profit/(loss) for the period (VII-VIII)</b>	<b>90.03</b>	<b>137.12</b>	<b>125.44</b>	<b>227.16</b>	<b>105.78</b>	<b>298.44</b>
X.	<b>Other comprehensive income, net of income tax</b>						
	A. Items that will not be reclassified to profit or loss						
	- Remeasurement of post-employment defined benefit plans	1.00	1.00	(2.50)	2.00	(5.00)	(4.54)
	- Income tax on the above item	(0.28)	(0.28)	0.70	(0.55)	1.40	1.26
	B. Items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other comprehensive income, net of income tax (X)</b>	<b>0.72</b>	<b>0.72</b>	<b>(1.80)</b>	<b>1.45</b>	<b>(3.60)</b>	<b>(3.28)</b>
XI.	<b>Total comprehensive income for the period (IX + X)</b>	<b>90.75</b>	<b>137.84</b>	<b>123.64</b>	<b>228.61</b>	<b>102.18</b>	<b>295.16</b>
XII.	Paid-up equity share capital (face value of Rs. 10/- each)	2,079.63	2,079.63	2,079.63	2,079.63	2,079.63	2,079.63
XIII.	<b>Earning per equity share: (of Rs. 10/-) (Not annualised) :</b>						
	(1) Basic (in Rs.)	0.43	0.66	0.60	1.09	0.51	1.44
	(2) Diluted (in Rs.)	0.43	0.66	0.60	1.09	0.51	1.44

**Notes:**

- 1 The above results have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on November 14, 2022. The above results has also been subjected to limited review by statutory auditors of the company.
- 2 Exceptional items represent the profit/ (loss) on sale of property, plant & equipment.
- 3 Figures of the previous periods have been regrouped and reclassified to confirm to the classification of current period, wherever necessary.

Coimbatore,  
November 14, 2022.

For Lotus Eye Hospital & Institute Limited  
  
**Ms. S. SANGEETHA**  
 Managing Director - DIN : 01859252





# Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014


Phone no: 0422-4229900, Fax: 0422-4229933, E-mail: companysecretary@lotuseye.org, Website: www.lotuseye.org

## Statement of Assets & Liabilities

Particulars	(Rs. in lakhs)	
	As at Sept 30, 2022 (Unaudited)	As at March 31, 2022 (Audited)
<b>Assets</b>		
<b>1. Non-current assets</b>		
(a) Property, plant and equipment	4,258.75	4,197.49
(b) Right of use asset	165.60	197.47
(c) Intangible assets	10.80	12.28
(d) Deferred tax assets (net)	43.81	52.30
(e) Other non-current assets	389.98	413.93
<b>Total Non-current assets (A)</b>	<b>4,868.94</b>	<b>4,873.47</b>
<b>2. Current assets</b>		
(a) Inventories	263.10	230.53
(b) Financial assets		
(i) Trade receivables	92.96	62.05
(ii) Cash and cash equivalents	213.50	378.89
(iii) Bank balances other than above	798.30	505.85
(c) Other current assets	157.23	108.89
<b>Total Current assets (B)</b>	<b>1,525.09</b>	<b>1,286.21</b>
<b>Total Assets (A + B)</b>	<b>6,394.03</b>	<b>6,159.68</b>
<b>Equity and Liabilities</b>		
<b>1. Equity</b>		
(a) Equity share capital	2,079.63	2,079.63
(b) Other equity	3,505.86	3,381.23
<b>Total Equity (C)</b>	<b>5,585.49</b>	<b>5,460.86</b>
<b>2. Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Financial liabilities		
(i) Lease Liabilities	43.96	67.05
(b) Provisions	(12.17)	34.83
(c) Other non-current liabilities	124.92	21.89
<b>Total Non-current liabilities (D)</b>	<b>156.71</b>	<b>123.77</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
(i) Trade payables		
(1) Total outstanding dues of micro enterprises and small enterprises.	43.94	39.70
(2) Total outstanding dues of creditors other than micro enterprises and small enterprises.	281.63	279.00
(ii) Lease Liabilities	45.44	56.76
(b) Other current liabilities	280.82	199.59
<b>Total Current liabilities (E)</b>	<b>651.83</b>	<b>575.05</b>
<b>Total Liabilities (D+E)</b>	<b>808.54</b>	<b>698.82</b>
<b>Total Equity and Liabilities (C+D+E)</b>	<b>6,394.03</b>	<b>6,159.68</b>

Coimbatore,  
November 14, 2022.

For Lotus Eye Hospital & Institute Limited

  
Ms. S. SANGEETHA  
Managing Director - DIN : 01859252



## Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014

Phone no: 0422-4229900, Fax: 0422-4229933, E-mail: companysecretary@lotuseye.org, Website: www.lotuseye.org

### Statement of Cash Flows

Particulars	(Rs. in lakhs)	
	Half year ended Sept, 2022 (Unaudited)	Half year ended Sept, 2021 (Unaudited)
<b>A. Cash flows from operating activities</b>		
Profit before tax and exceptional item	305.99	145.53
<i>Adjustments:</i>		
Depreciation and amortisation	143.20	112.25
Interest income	(17.96)	(22.14)
Rental income	(21.30)	(13.25)
Finance costs	5.64	5.86
<b>Operating cash flow before working capital changes</b>	<b>415.57</b>	<b>228.25</b>
<b>Change in operating assets &amp; liabilities :</b>		
Inventories	(32.57)	(32.09)
Trade receivables	(30.91)	18.10
Other assets (current and non-current)	(24.20)	(195.09)
Trade payables	6.87	33.99
Provisions	(45.00)	(1.00)
Other liabilities (current and non-current)	80.26	17.47
<b>Cash generated from operating activities</b>	<b>370.02</b>	<b>69.63</b>
Taxes paid (Net)	(70.76)	(24.09)
<b>Net cash generated from operating activities (A)</b>	<b>299.26</b>	<b>45.54</b>
<b>B. Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(171.65)	(81.66)
Proceeds from the sale of property, plant and equipment	0.22	0.13
Interest income	17.96	22.14
Rental income	21.30	13.25
<b>Net cash generated from / (used in) investing activities (B)</b>	<b>(132.17)</b>	<b>(46.14)</b>
<b>C. Cash flows from financing activities</b>		
Finance costs	(5.64)	(5.86)
Dividend paid	(103.98)	(103.98)
(Payment of) / Increase in lease liabilities	(34.40)	75.60
<b>Net cash (used in) / generated from financing activities (C)</b>	<b>(144.02)</b>	<b>(34.24)</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>23.07</b>	<b>(34.84)</b>
Cash and cash equivalents at the beginning of the year	879.30	989.24
<b>Cash and equivalents at the end of the year</b>	<b>902.37</b>	<b>954.39</b>
Cash on hand	9.70	7.23
Balance with banks	892.67	947.16

**Note:**

Cash and Bank Balances do not include dividends payable (including unclaimed dividend) Rs. 109.42 Lakhs as on September 30, 2022 and Rs. 106.06 Lakhs as on September 30, 2021

Coimbatore,  
November 14, 2022.

For Lotus Eye Hospital & Institute Limited

*Sangeetha*  
Ms. S. SANGEETHA  
Managing Director - DIN : 01859252

Format for disclosure of related party transactions every six months (see Note 4)

Annex

S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured		
1.	LEHIL*		LVRT#		M/D of LEHIL is Managing Trustee of LVRT	Rendering of services	50 Lakhs	21.30 Lakhs	-	-	NA	NA	NA	NA	NA	NA	NA	NA	
2.	LEHIL*		LVRT#		M/D of LEHIL is Managing Trustee of LVRT	Availing of services	40 Lakhs	30.10 Lakhs	-	-	NA	NA	NA	NA	NA	NA	NA	NA	
3.	LEHIL*		LVRT#		M/D of LEHIL is Managing Trustee of LVRT	Electricity Charges	20 Lakhs	6.22 Lakhs	-	-	NA	NA	NA	NA	NA	NA	NA	NA	
4.	LEHIL*				CEO is Managing Director of Combatores Kidney Centre	Rendering of services	12 Lakhs	0.96 Lakhs	-	-	NA	NA	NA	NA	NA	NA	NA	NA	
5.	LEHIL*				Promoter/Managing Director Sangeetha Sundaram Soodry	Employee Benefit Expenses	-	6 Lakhs	-	-	NA	NA	NA	NA	NA	NA	NA	NA	

For Lotus Eye Hospital and Institute Ltd.

  
Company Secretary

6	LEHIL*	KS Ramalingam	Key Managerial Personnel	Employee Benefit Expenses	-	6 Lakhs	-	-											
7	LEHIL*	Kavetha Sundaramoorthy	Promoter	Sitting Fees	-	1 Lakh	-	-											
8	LEHIL*	DR Kaarthikeyan	Director	Sitting Fees	-	1 Lakh	-	-											
9	LEHIL*	Yogesh shah	Director	Sitting Fees	-	1 Lakh	-	-											
10	LEHIL*	R Subramanian	Director	Sitting Fees	-	1 Lakh	-	-											
11	LEHIL*	S Natesan	Director	Sitting Fees	-	1 Lakh	-	-											
12	LEHIL*	Alagiriswamy	Director	Sitting Fees	-	1 Lakh	-	-											
13	LEHIL*	Achuth menon	Company Secretary	Employee Benefit Expenses	-	4.86 Lakhs	-	-											
14	LEHIL*	Ramanujam Repunathan	Chief Financial Officer	Employee Benefit Expenses	-	6.26 Lakhs													
15	LEHIL*	Sangeetha Sundaramoorthy	Promoter/Managing Director	Dividend paid	-	19.59 Lakhs													

For Lotus Eye Hospital and Institute Ltd.

  
Company Secretary



16	LEHIL*	KS Ramaningam	Key Managerial Personnel	Dividend paid	-	1.49 Lakhs												
17	LEHIL*	Kavetha Sundaram oorthy	Promoter	Dividend paid		19.53 Lakhs												
18	LEHIL*	Dr. Rajkumar	Promoter	Dividend paid		18.56 Lakhs												
19	LEHIL*	V. Saroja	Promoter	Dividend paid		0.00 Lakhs												
20	LEHIL*	S. A. Karuppasamy	Promoter	Dividend paid		0.00 Lakhs												

\*Lotus Eye Hospital and Institute Limited  
# Lotus Vision Research Trust

For Lotus Eye Hospital and Institute Ltd.

  
Company Secretary